![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/06/2894638/0/en/Anthos-Therapeutics-Announces-84-of-Eligible-Patients-Have-Transitioned-to-Abelacimab-in-the-AZALEA-TIMI-71-Extension-Study-of-Atrial-Fibrillation-Patients-at-a-Moderate-to-High-Ri.html
https://endpts.com/weeks-after-closing-bristol-myers-deal-karunas-ex-ceo-heads-to-blackstone-backed-anthos/
https://www.globenewswire.com/news-release/2024/04/22/2867058/0/en/Anthos-Therapeutics-Announces-Appointment-of-Bill-Meury-as-CEO.html
https://endpts.com/anthos-blood-thinner-cuts-the-risk-of-bleeding-amid-race-to-develop-safer-anticoagulants/
https://www.globenewswire.com/news-release/2023/06/26/2694288/0/en/Anthos-Therapeutics-Supported-Global-Survey-of-3000-Patients-Prescribed-Anticoagulants-Detailing-Impact-of-Patient-Relevant-Bleeding-PRB-Presented-at-ISTH-2023.html
https://www.globenewswire.com/news-release/2023/06/08/2684978/0/en/Regulatory-Authorities-in-China-and-Japan-Approve-Clinical-Trials-for-Anthos-Therapeutics-Dual-Acting-Factor-XI-XIa-Inhibitor-Abelacimab.html
https://www.globenewswire.com/news-release/2023/05/09/2664607/0/en/New-Assessment-Scale-to-Measure-Adherence-to-Oral-Anticoagulants-Based-on-Impact-of-Patient-Relevant-Bleeding-in-Atrial-Fibrillation-Presented-at-ISPOR-2023.html